CAR-T cell therapy, or chimeric antigen receptor T cell therapy, is best known for its application in oncology, where the results have been life-changing for patients. The therapy for autoimmune diseases made headlines in September 2022 when five patients with systemic lupus erythematosus (SLE) were confirmed to be in remission for an average of eight months after treatment.